November 24, 2020 11:14 AM EST
R&D

Gen­mab ax­es an ADC de­vel­op­ment pro­gram af­ter the da­ta fail to im­press

John Carroll

Editor & Founder

Gen­mab $GMAB has opt­ed to ax one of its an­ti­body-drug con­ju­gates af­ter watch­ing it flop in the clin­ic.

The Dan­ish biotech re­port­ed Tues­day that it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

‘Just the be­gin­ning’: No­bel Prizes show the AI era has ar­rived in biotech

Ex­clu­sive Q&A: FDA's prin­ci­pal deputy com­mis­sion­er on tak­ing over for Califf, ad­comms, ac­cel­er­at­ed ap­provals and more

CMS looks to $2 out-of-pock­et cap for some com­mon­ly used gener­ic drugs

AI biotech in­sitro part­ners with Lil­ly on meta­bol­ic dis­ease drugs

GSK to pay up to $2.2B to set­tle al­most all Zan­tac-re­lat­ed court cas­es

Il­lu­mi­na's pitch for new ma­chines: You, too, can se­quence DNA

A service from the Financial Times